
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ISLA101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Examine the Effects of Oral Fenretinide
Details : ISLA101 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dengue.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 30, 2024
Lead Product(s) : ISLA101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fenretinide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Beyond Drug Development
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers
Details : Fenretinide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 26, 2023
Lead Product(s) : Fenretinide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Beyond Drug Development
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ISLA-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : State University of New York
Deal Size : Inapplicable
Deal Type : Inapplicable
Island Pharmaceuticals Granted Key Patent for ISLA-101 in the United States
Details : ISLA-101, has been granted by the United States Patent & Trademark Office. ISLA-101 is a drug with a very well-known safety profile, being repurposed for mosquito borne viruses.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 19, 2021
Lead Product(s) : ISLA-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : State University of New York
Deal Size : Inapplicable
Deal Type : Inapplicable

Contact Us!